Lupus discovery may pave way to better-designed COX-2 inhibitors
Main Category: LupusArticle Date: 16 Mar 2004 - 0:00 PDT
'Lupus discovery may pave way to better-designed COX-2 inhibitors'
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
In an important development in the treatment of lupus as well as certain cancers, scientists at the Feinberg School of Medicine at Northwestern University have discovered how autoimmune lupus T cells stave off programmed cell death and drive production of autoantibodies directed against the body's own DNA.
Syamal Datta, M.D., and colleagues found that lupus T cells increase production of an enzyme called cyclooxygenase 2 (COX-2), which helps trigger inflammation, in tandem with another molecule called c-FLIP, which then prevents the autoimmune T cells from self-destructing.
Using commonly prescribed drugs called COX-2 inhibitors, which suppress COX-2 activity and, as a result, inflammatory chemicals called prostaglandins, the Northwestern researchers caused autoimmune T cells to die and blocked lupus autoimmunity.
Results of their study, published in the April issue of Nature Medicine, may pave the way for the design of better COX-2 inhibitors with less kidney toxicity or other candidate drugs that interfere with the lupus T cell's death resistance pathway, said Datta, who is Solovy Professor of Medicine and professor of microbiology/immunology at the Feinberg School.
Currently, COX-2 inhibitors are widely prescribed to treat rheumatoid arthritis and other inflammatory conditions, and have been tested for use in a number of cancers, including colorectal cancer.
Most unexpectedly, the researchers found that only some COX-2 inhibitors have a beneficial effect in lupus, which may depend on their structural peculiarity and not because they inhibit prostaglandin production and reduce inflammation -- something all COX-2 inhibitors do.
COX-2 inhibitors also have been used, with limited success, to treat patients with lupus and in laboratory models of lupus, but in doses much lower than the concentration required to achieve cell death and elimination of autoimmune T cells, Datta said.
Datta's co-researchers were Luting Xu, Li Zhang, Yajun Yi and Hee-Kap Kang. Yajun Yi is now at Vanderbilt University, Nashville.
Contact: Elizabeth Crown
e-crown@northwestern.edu
312-503-8928
Northwestern University
Visit our lupus section for the latest news on this subject.
MLA
26 May. 2012. <http://www.medicalnewstoday.com/releases/6569.php>
APA
http://www.medicalnewstoday.com/releases/6569.php.
Please note: If no author information is provided, the source is cited instead.
Add Your Opinion On This Article
'Lupus discovery may pave way to better-designed COX-2 inhibitors'Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




